Protalix Reports Phase I Clinical Study Results for PRX-106 Showed Favorable Safety, Tolerability Profile Activity
August 03, 2015 at 07:34 AM EDT
Protalix BioTherapeutics, Inc. (NYSE: PLX) announced today positive clinical study results from the Company's Phase I trial of PRX-106, ...